The Companion Diagnostics (CDx) Market 2014-2024

Description

The Companion Diagnostics (CDx) MarketThe Companion Diagnostics (CDx) Market 2014-2024 PR Newswire LONDON, January 9, 2014 Our new study shows you the commercial potential of companion diagnostics What does the future hold for the companion diagnostics market? Visiongain's brand new report shows you the potential revenues to 2024, assessing data, trends, opportunities and prospects there. Our 145 page report provides 103 tables, figures and charts. Discover the most lucrative areas in the industry and the future market prospects. You will see financial results, interviews, trends, opportunities, and revenue predictions. Forecasts from 2014-2024 and other analyses show you commercial prospects Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT), company profiles and commercial developments. Read full transcripts of two exclusive expert opinion interviews from leading industry specialists informing your understanding and allowing you to assess prospects for investments and sales: - Biomonitor A/S, Arsalan Kharazmi, PhD, CEO - Ambry Genetics, Ardy Arianpour, MBA, Senior Vice President of Business Development You will find prospects for key submarkets Growth in this market will be fuelled by an increasing demand for safer and more efficacious medicines.

Informations

• Publié par: visiongain
• Publié le: 09 janvier 2014
• Nombre de lectures: 27
• Langue: English

Extrait

The Companion Diagnostics (CDx) Market 2014-2024

PR Newswire

LONDON, January 9, 2014

Our new study shows you the commercial potential of  companion diagnostics

What does the future hold for the companion diagnostics market? Visiongain's brand new report shows you the potential revenues to 2024, assessing data, trends, opportunities and prospects there.

Our 145 page report provides 103 tables, figures and charts. Discover the most lucrative areas in the industry and the future market prospects. You will see financial results, interviews, trends, opportunities, and revenue predictions.   

Forecasts from 2014-2024 and other analyses show you commercial prospects

Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT), company profiles and commercial developments. Read full transcripts of two exclusive expert opinion interviews from leading industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
- Biomonitor A/S, Arsalan Kharazmi, PhD, CEO    
- Ambry Genetics, Ardy Arianpour, MBA, Senior Vice President of Business Development
    
You will find prospects for key submarkets

Growth in this market will be fuelled by an increasing demand for safer and more efficacious medicines. In addition to analyses of the overall world market, you see revenue forecasting of two submarkets to 2024:
•    Theranostics
•    Other Companion Diagnostics

Our investigation shows business research and analysis with individual revenue forecasts and discussions.

To see an exec summary of this report please email Sara Peerun on [e-mail]

Prospects for leading countries are shown to 2024

Events and progress worldwide will influence the market. Regulatory authorities mandating the approval of diagnostics simultaneously with therapies will propel the companion diagnostics market in the coming years.

You will discover individual revenue forecasts to 2024 for 9 leading national markets:
•    US
•    Japan
•    UK
•    Germany
•    France
•    Spain
•    Italy
•    China
•    India
•    RoW

Greater uptake of existing technology worldwide will also stimulate the industry and market.

Leading companies and potential for market growth

Overall world revenue for companion diagnostics will reach $3bn in 2014. M&A activity in the companion diagnostics market has experienced explosive growth in recent years. We expect this trend to continue as most pharmaceutical companies do not have an in-house diagnostic capability for either the development of a companion diagnostic or the commercialisation of the test once the drug is approved.  

Our research profiles leading companies, assessing their technologies and products. You will see which technologies and organisations hold the greatest potential.

In particular, we profile these leading organisations:
•    Roche
•    Qiagen
•    Myriad Genetics
•    Siemens Diagnostics
•    Abbott Molecular
•    BioMérieux
•    Danaher

In general, a company profile gives you the following information:
•    Discussion of a company's activities and outlook
•    Recent financial results
•    Assessment of recent developments - mergers and acquisitions (M&A), new products, and collaborations

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues affect the companion diagnostics market?

Our study lets you assess industry trends and outlooks. You will find discussions, including qualitative analyses:
•    Reimbursement challenges
•    Drive towards personalised medicine and support from regulatory authorities
•    Increasing compliance and reduction of adverse reactions
•    Increasing development and employment of biomarkers at earlier stages of development
•    International expansion - targeting emerging national markets
•    Complex business models and business partnerships
•    Lack of clear regulatory guidelines

To see an exec summary of this report please email Sara Peerun on [e-mail]

How The Companion Diagnostics (CDx) Market 2014-2024  report helps you

In summary, our report gives you the following knowledge:
•    Revenues forecasts to 2024 for the overall world companion diagnostics market and 2 submarkets - discover that industry's prospects, finding promising places for investments and revenues
•    Assess 7 leading companies, and others, discovering activities and outlooks
•    Market forecasting to 2024 for 9 key national markets: US, Japan, Germany, UK, France, Spain, Italy, China, India and RoW.
•    View opinions from our survey, seeing two interviews with authorities
•    Investigation of competition and opportunities influencing sales
•    Discussion of what stimulates and restrains the industry and market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed on business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunities. See there how you could benefit your research, analyses, and decisions. Also see how you can save time and get recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for companion diagnostics. You will find data, trends and predictions. Please order our report now.

To request an exec summary of this report please email Sara Peerun at [e-mail] or call Tel : [phone]

Or click on http://www.visiongain.com/Report/1173/The-Companion-Diagnostics-%28CDx%29-Market-2014-2024

Companies Listed in this Report:

Abbott Molecular
Agendia
Alacris Theranostics GmbH
AltheaDx
Ambry Genetics
Amgen
ARGENE
ARIAD Pharmaceuticals
Astellas
AstraZeneca
Beckman Coulter
BioMérieux
Biomonitor
Boehringer Ingelheim
Brain Resource Company
Bristol-Myers Squibb
CancerGuide Diagnostics
Caprion Proteomics
Caris Life Sciences
Celera (acquired by Quest Diagnostics in May 2011)
Cell Signalling Technologies
Cephalon
Cepheid
ChemGenex Pharmaceuticals
Clinical Reference Laboratory
CompanDx
Crescendo Bioscience
Curidium Medica
Cytyc Corporation
Dako
Danaher
DiagnoCure
Dx assays
DxS
Eli Lilly
Endocyte
Exosome Diagnostics
Flagship Biosciences
Foundation Medicine
Genentech
Genetix
Genfit
GenMark Diagnostics
Genome Institute
Genomic Health
GSK
Hatteras Venture Partners
HistologiX
Hospices Civils de Lyon
Ibis Biosciences, Inc.
ImCloneSystems
InDex Pharmaceuticals
Institute Merieux
Institute Pasteur
Intersouth Partners
Inverness Medical Innovations
Invivoscribe
Ipsen
Ipsogen
Iris International and Aperis Technologies
Janssen Pharmaceutical
Kimball Genetics (a division of LabCorp)
Knome, Inc
Lab21
Laboratory for Personalized Molecular Medicine
Leica
Leica Microsystems
Life Technologies
Merck
Molecular MD
Myriad Genetics
Myriad RBM
Nanosphere
Novartis
Opko Health
OSI Pharmaceuticals
Oxford BioTherapeutics (earlier Oxford  Genome  Sciences)
Pfizer
PharmaMar
Progenika Biopharma
Prometheus
Qiagen
Quanterix
Quintiles Transnational Corporation
Randox Pharma Services
RAS Lifesciences Pvt. Ltd (RAS)
RiboMed Biotechnologies
Roche Molecular Systems
Rules-Based Medicines Inc.
Saladax Biomedical
Siemens
Signal Genetics
Sirius Genetics
Skyline Diagnostics
STARLIMS technologies
Takeda
Target Discovery
TcLand Expression
Telegraph Hill Partners
Tesaro
Teva Pharmaceutical Industries
Theranostics (NZ)
Theranostics Health
Thermo Fisher Scientific  Inc.
Third Wave Technologies (a wholly owned subsidiary of Hologic)
TIB MolBiol
Tocagen
Tragara Pharmaceuticals
Transgene
Transgenomic
TrimGen Corporation
Unilabs
Ventana Medical Systems
ViiV Healthcare
Vision Systems
Weisenthal Cancer Group
Zinfandel

Other Organisations Mentioned in This Report

Cancer Research UK
Columbia University
European Medicines Agency (EMA)
Food and Drug Administration (FDA)
Haute Autorité de Santé (HAS)
Medical Research Council
National Health Service (NHS)
National Institute for Health and Care Excellence  (NICE)
National Institutes of Health (NIH)
ServizioSanitarioNazionale (SSN)
The Association of British Pharmaceutical Industries (ABPI)
Tufts Center for the Study of Drug Development

To see an exec summary of this report please email Sara Peerun on [e-mail]